BIOMARCADORES PARA DIAGNÓSTICO DE ENFERMEDAD INFLAMATORIA INTESTINAL

VolverVolver

Resultados 54 resultados LastUpdate Última actualización 11/07/2020 [16:55:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



Página1 de 3 nextPage   por página


DEVELOPMENT OF MICROBIAL BIOSENSORS FOR INTESTINAL INFLAMMATION

NºPublicación: US2020209261A1 02/07/2020

Solicitante:

BAYLOR COLLEGE MEDICINE [US]

WO_2018209318_A2

Resumen de: US2020209261A1

Embodiments of the disclosure include systems, methods, and compositions for detection of imminent onset of a symptom of a gut inflammation medical condition. The disclosure also concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual with IBD.

traducir

METHODS OF TREATING INFLAMMATORY BOWEL DISEASES THAT TARGET RIPK2

NºPublicación: WO2020139748A1 02/07/2020

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

Resumen de: WO2020139748A1

Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis in a subject, with an antagonist of RIPK2 activity or expression. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with the antagonist to RIPK2 activity or expression, as described herein.

traducir

GP2 ISOFORMS AND THEIR USE IN AUTOANTIBODY CAPTURE

NºPublicación: US2020209258A1 02/07/2020

Solicitante:

GA GENERIC ASSAYS GMBH [DE]

Resumen de: US2020209258A1

The invention relates to a method for binding or capturing autoantibodies directed to various Glycoprotein 2 (GP2) isoforms. In particular the invention provides an in vitro method for the diagnosis of an autoimmune disorder by the detection of autoantibodies that bind one or more isoforms of GP2. The invention is characterized by the provision of multiple isoforms of GP2 as autoantibody targets and encompasses the practical utilization of the finding that the isoform specificity of anti-GP2 autoantibodies enables determination of particular autoimmune diseases. The invention also provides a system and kit developed for carrying out the claimed method. The present invention is useful for determining whether a sample from an individual comprises autoantibodies associated with an autoimmune disease, and for differentiating between multiple autoimmune diseases that exhibit similar symptoms, such as Celiac disease (CeD), Crohn's disease (CD), primary sclerosing cholangitis (PSC), and/or ulcerative colitis (UC).

traducir

Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

NºPublicación: AU2020203468A1 18/06/2020

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

US_2018196063_A1

Resumen de: AU2020203468A1

The present invention describes methods, assays, and systems of diagnosing, selecting and treating irritable bowel syndrome (IBS) based on a subject's level of anti-vinculin and anti CdtB antibodies. IBS can be distinguished from inflammatory bowel (IBD) disease using the methods, assays, and systems described herein.

traducir

MITIGATION AND REVERSAL OF FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION AND RELATED SIGNALING PATHWAYS

NºPublicación: US2020190203A1 18/06/2020

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

JP_2020033379_A

Resumen de: US2020190203A1

The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.

traducir

MARKERS FOR DISEASE AND DISEASE EXTENT IN INFLAMMATORY BOWEL DISEASE

NºPublicación: US2020191803A1 18/06/2020

Solicitante:

UNIV OTTAWA [CA]

CA_3067062_A1

Resumen de: US2020191803A1

A method for determining a presence of inflammatory bowel disease in a subject. The method involves providing a gut sample obtained from a subject; measuring a level in said gut sample of one or more proteins, wherein said one or more proteins comprises at least one of: leukotriene A-4 hydrolase, catalase, transketolase, thioredoxin domain containing protein 17, vasodilator-stimulated phosphoprotein and thymosin beta-10; and comparing said measured level of each of said one or more proteins to a corresponding protein level for a normal subject. A method for determining a presence of pancolitis in a subject with ulcerative colitis is also provided.

traducir

METHOD OF DIAGNOSING A DYSBIOSIS

NºPublicación: US2020181674A1 11/06/2020

Solicitante:

SMARTDNA PTY LTD [AU]

AU_2020202974_A1

Resumen de: US2020181674A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).

traducir

ASSESSMENT AND MONITORING OF MUCOSAL HEALING IN CHILDREN AND ADULTS WITH CROHN'S DISEASE

NºPublicación: WO2020117795A1 11/06/2020

Solicitante:

PROMETHEUS BIOSCIENCES INC [US]

Resumen de: WO2020117795A1

Provided are methods for assessing or monitoring mucosal healing in an adult or pediatric patient with Crohn's Disease (CD). Some embodiments include receiving or detecting levels of biomarkers. In some embodiments, the biomarkers include Ang1, Ang2, CEACAM1, VCAM1, TGFα, CRP, SAA1, MMP-1, MMP-2, MMP-3, MMP-9, EMMPRIN, or IL-7. Some embodiments include applying a mathematical algorithm to the biomarker levels to produce a Endoscopic Healing Index (EHI) score for the adult or pediatric patient.

traducir

BIOMARKERS FOR ASSESSING THE RESPONSE STATUS FOR TREATMENT OF INFLAMMATORY CONDITION OR DISEASE AFFECTING THE DIGESTIVE TRACT SUCH AS INFLAMMATORY BOWEL DISEASE IN HUMAN PATIENTS

NºPublicación: US2020181706A1 11/06/2020

Solicitante:

OSE IMMUNOTHERAPEUTICS [FR]
CT HOSPITALIER UNIVERSITAIRE NANTES [FR]

WO_2019025624_A1

Resumen de: US2020181706A1

The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TNFalpha agents, for treatment with anti-α4β7 agents or with both anti-TNFalpha agent and anti-α4β7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-α4β7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease. The invention describes a method of in vitro assessing whether a treatment with anti-TNFalpha agent or with anti-α4β7 agent may be useful in a human patient suffering from inflammatory condition or disease, in particular when said condition or disease is a chronic and/or relapsing one, particularly a gastrointestinal, more particularly intestinal, inflammatory condition or disease which is eligible for treatment with anti-TNFalpha agent or respectively with anti-α4β7 agent. In a specific embodiment the method is suitable to assess whether such patient would be non-responsive to treatment with such anti-TNFalpha agent or respectively with anti-α4β7 agent and comprising determining a molecular signature in a biological sample previously obtained from said human patient.

traducir

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE

NºPublicación: US2020181244A1 11/06/2020

Solicitante:

CORIXA CORP [US]

US_2018362622_A1

Resumen de: US2020181244A1

Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.

traducir

LACTIC ACID BACTERIUM OF SPECIES LACTOBACILLUS PLANTARUM ISOLATED FROM CRUCIAN CARP SUSHI AND METHOD FOR SCREENING SAME

NºPublicación: WO2020116365A1 11/06/2020

Solicitante:

NIPPON SUISAN KAISHA LTD [JP]

Resumen de: WO2020116365A1

[Problem] To provide a novel lactic acid bacterium having a high functionality that is isolated from crucian carp sushi. [Solution] Provided is a lactic acid bacterium belonging to the species Lactobacillus plantarum, which is isolated from crucian carp sushi and has at least one effect selected from the group consisting of effects of inhibiting viral infection, enhancing NK activity, reducing lipids, lowering blood neutral fat level and improving bowel movement. Also provided is a lactic acid bacterium that is Lactobacillus plantarum subsp. plantarum FS-1C strain.

traducir

METHODS OF STRATIFYING AND TREATING A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS

NºPublicación: WO2020113116A1 04/06/2020

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

Resumen de: WO2020113116A1

Described herein are methods and systems for identifying subpopulations of patients having Crohn ́s disease, including populations at risk of developing structuring or other severe disease, and populations susceptible to success or failure with surgical intervention. Further provided are therapies useful for treating subpopulations of patients having Crohn ́s disease.

traducir

USE OF BACTERIAL EXTRACELLULAR VESICLES AS A BIOMARKER FOR INTESTINAL BARRIER PERMEABILITY AND MICROBIAL DYSBIOSIS

NºPublicación: WO2020104577A1 28/05/2020

Solicitante:

UNIV GENT [BE]

Resumen de: WO2020104577A1

The present invention relates to a method of analyzing a biofluid of a subject for the presence of bacterial extracellular vesicles (EV), said method comprising the steps of a) extracting bacterial EV from said biofluid, b) analyzing said bacterial EV-extracted molecular patterns for the presence of a disease marker, wherein said disease marker is a disease-specific molecular pattern of said subject; and said subject comprising patients diagnosed with HIV, IBD or cancer or said subject receiving a treatment.

traducir

PREDICTING A TREATMENT RESPONSE IN INFLAMMATORY BOWEL DISEASE

NºPublicación: WO2020104705A2 28/05/2020

Solicitante:

UNIV LEUVEN KATH [BE]

Resumen de: WO2020104705A2

In general the present invention concerns a method for predicting the therapeutic outcome of a treatment of in inflammatory bowel disease for anti-TNF agents, anti- α4β7-intcgrin agents and/or anti- IL-12/23 agents. The method defines which the agents are likely to provide the best healing effect for a particular patients affected by an inflammatory bowel disease. In particular the method predicts the therapeutic outcome of a treatment of anti-TNF agents in inflammatory bowel disease.

traducir

CAPTURING CROWD WISDOM IN INDIVIDUALIZED TREATMENT PLANS

NºPublicación: US2020168315A1 28/05/2020

Solicitante:

VIVANTE HEALTH INC [US]

Resumen de: US2020168315A1

Embodiments of the invention include systems and methods for capturing crowd wisdom to be tested for individualized treatment plans. These systems and methods include data mining crowd sourced health related information and unstructured medical narratives and storytelling to identify treatment plans and general techniques that individuals with chronic diseases/symptoms, including but not limited to IBD and other immune invisible neglected and stigmatized diseases, use to improve their general health and wellbeing. A system for testing the treatments effectiveness in a population and then in an individual is also disclosed.

traducir

METHODS AND USES OF INFLAMMATORY BOWEL DISEASE BIOMARKERS

NºPublicación: US2020165677A1 28/05/2020

Solicitante:

STAPPENBECK THADDEUS [US]
KAIKO GERARD [US]
LIU TA CHIANG [US]

Resumen de: US2020165677A1

Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1 (PAI-1) inhibitor or tissue plasminogen activator (tPA).

traducir

METHODS AND USES OF INFLAMMATORY BOWEL DISEASE BIOMARKERS

NºPublicación: EP3655433A1 27/05/2020

Solicitante:

UNIV WASHINGTON [US]
STAPPENBECK THADDEUS [US]
KAIKO GERARD [US]
LIU TA CHIANG [US]

CN_111212851_A

Resumen de: WO2019018571A1

Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1(PAI-1) inhibitor or tissue plasminogen activator (tPA).

traducir

CIRCULATING FIBROBLAST ACTIVATION PROTEIN AS BIOMARKER FOR THE DIAGNOSIS OF AN INFLAMMATORY BOWEL DISEASE

NºPublicación: WO2020099378A1 22/05/2020

Solicitante:

INTHENA S R L [IT]

Resumen de: WO2020099378A1

The present invention concerns the field of inflammatory bowel diseases, and in particular it relates to the use circulating fibroblast activation protein, as a biological marker for the diagnosis of Crohn's disease or Ulcerative colitis in a blood sample. In a further aspect, the present invention relates to a method for the diagnosis of an Inflammatory Bowel Disease such as Crohn's disease.

traducir

METHODS AND COMPOSITIONS FOR PREDICTION OF RESPONSE TO A THERAPY OF AN INFLAMMATORY BOWEL DISEASE

NºPublicación: WO2020102519A1 22/05/2020

Solicitante:

JANSSEN BIOTECH INC [US]

Resumen de: WO2020102519A1

Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.

traducir

METHODS OF TREATING AND DIAGNOSING IBD ASSOCIATED WITH R. GNAVUS AND/OR R. GNAVUS GROUP IBD COLONIZATION

NºPublicación: US2020155617A1 21/05/2020

Solicitante:

BROAD INST INC [US]
MASSACHUSETTS GEN HOSPITAL [US]
HARVARD COLLEGE [US]

WO_2018195448_PA

Resumen de: US2020155617A1

This application provides for methods of treatment for IBD, especially in subjects who have R. gnavus species or R. gnavus group IBD strains as a component of their microbiome. The application also provides for methods of diagnosing IBD, as well as kits for use in the claimed methods.

traducir

Method of diagnosing a dysbiosis

NºPublicación: AU2020202974A1 21/05/2020

Solicitante:

SMARTDNA PTY LTD [AU]

US_2020181674_A1

Resumen de: AU2020202974A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).

traducir

INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO

NºPublicación: US2020157495A1 21/05/2020

Solicitante:

TRACT PHARMACEUTICALS INC [US]

WO_2018204913_PA

Resumen de: US2020157495A1

The present invention addresses IBD from the standpoint of mucosal stem cells cloned from defined regions of the gastrointestinal tract. In the case of pediatric Crohn's disease, for example, isolation of those stem cells according to the methods of the present invention reveals a pattern of inflammatory gene expression in stem cells from the terminal ileum and colon that is epigenetically maintained despite months of continuous cultivation in the absence of immune or stromal cells, or of intestinal microbes. Superimposed on this distributed inflammatory phenotype is a differentiation defect that profoundly and specifically alters the mucosal barrier properties of the terminal ileum. The co-existence of diseased and normal stem cells within the same endoscopic biopsies of Crohn's disease patients implicates an epigenetically enforced heterogeneity among mucosal stem cells in the dynamics of this condition.

traducir

METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: US2020149087A1 14/05/2020

Solicitante:

MEHARRY MEDICAL COLLEGE [US]

CN_110719960_A

Resumen de: US2020149087A1

Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.

traducir

DIAGNOSIS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE

NºPublicación: US2020149110A1 14/05/2020

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

US_2015259748_A1

Resumen de: US2020149110A1

This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.

traducir

Methods and uses of inflammatory bowel disease biomarkers

Nº publicación: AU2018304283A1 07/05/2020

Solicitante:

UNIV WASHINGTON
STAPPENBECK THADDEUS
KAIKO GERARD
LIU TA CHIANG

CN_111212851_A

Resumen de: AU2018304283A1

Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1(PAI-1) inhibitor or tissue plasminogen activator (tPA).

traducir

Página1 de 3 nextPage por página

punteroimgVolver